Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTA vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

ENTA Overall Winner 6-Pillar Tally: ENTA 3 – 2 ANNX (1 Tie) Matrix Metrics: ENTA 5 – 5 ANNX

As of Nov 16, 2026, Enanta Pharmaceuticals, Inc (ENTA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas ANNX carries 44.6/100 (HOLD) at $3.62 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ENTA earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. ANNX 44.6/100 HOLD) and 0.89β · 58% Vol risk profile, whereas ANNX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTA vs ANNX
ENTA NASDAQ Head-to-Head Winner
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.62
-7.53% 1D
Market Cap $757.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.69β · 64% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 42.0 Fund 54.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $3.98 · SMA50: $4.00

6-Pillar Scorecard Institutional Category Breakdown (ENTA 3 – 2 ANNX)

Columns: Metric · ENTA · ANNX
1. Valuation Multiples ENTA
Forward P/E 44.0x N/M
Trailing P/E 44.0x N/M
PEG Ratio N/M N/M
EV / Revenue 5.3x N/M
2. Growth & Scale ANNX
Revenue Growth (YoY) -21.6% +0.0%
Earnings Growth (YoY) -66.2% +0.0%
TTM Revenue (USD) $65M N/A
Market Cap $326.2M $757.3M
3. Profitability & Quality ANNX
Gross Margin 100.0% N/A
Operating Margin -90.0% 0.0%
Net Profit Margin -96.9% 0.0%
Return on Equity (ROE) -70.1% -130.8%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$37M -$190M
Cash Flow Margin -56.6% N/A
Net Cash / Leverage $22M Net Debt (0.55x D/E) $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 78.7% (11th %ile) 209.2% (40th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) 0.75x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTA (5) vs ANNX (5)
Institutional Metric ENTA ANNX Criterion Row Edge
Market Capitalization
Scale
$326.2M $757.3M Larger Scale ANNX
Trailing P/E Ratio
Valuation
44.0x N/M Lower Multiple ENTA
Forward P/E Ratio
Valuation
44.0x N/M Lower Multiple ENTA
Revenue Growth (YoY)
Growth
-21.6% +0.0% Higher Growth ANNX
Operating Margin (TTM)
Profitability
-90.0% 0.0% Higher Margin ANNX
Net Profit Margin
Profitability
-96.9% 0.0% Higher Margin ANNX
Return on Equity (ROE)
Capital Efficiency
-70.1% -130.8% Higher ROE ENTA
52-Week Range Position
Momentum
10% ($10–$17) 23% ($3–$7) Stronger Trend ANNX
Beta / 30D Volatility
Risk Regime
0.89β · 58% Vol 1.69β · 64% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 44.6 / 100 (HOLD) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
$65M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M ($22M Net Debt (0.55x D/E)) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANNX +9.09 pp
ENTA: -2.79% · ANNX: +6.3%
3M Horizon ENTA +12.47 pp
ENTA: -18.87% · ANNX: -31.34%
6M Horizon ENTA +7.14 pp
ENTA: -19.78% · ANNX: -26.92%
1Y Horizon ANNX +43.2 pp
ENTA: -7.94% · ANNX: +35.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTA vs ANNX. Trailing 12-month operating profitability (ENTA -90.0% vs ANNX 0.0%) and valuation multiples (ENTA 44.0x vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ENTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$65M
Gross Margin100.0%
Op. Margin-90.0%
ROE / Fwd P/E-70.1% · 44.0x
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
87d in phase · OBV DISTRIBUTION
Current IV 209.2%
IV Percentile 40th %ile
Put/Call OI Skew 0.75x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $757.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTA vs ANNX Key Questions & Quantitative Answers

As of Nov 16, 2026, Enanta Pharmaceuticals, Inc (ENTA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas ANNX carries 44.6/100 (HOLD) at $3.62 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTA earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. ANNX 44.6/100 HOLD) and 0.89β · 58% Vol risk profile, whereas ANNX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANNX leads the Growth & Scale pillar: ENTA posts -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ENTA generates $65M in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, ENTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

ENTA screens cheaper on headline valuation multiples. ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTA (-70.1% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk). By comparison, ANNX carries 209.2% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.75x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.